Latest News and Press Releases

Laudio releases 2nd edition of “Leader Inspired Work” featuring HR insights, expert perspectives & 300+ actionable tips for frontline healthcare leaders.

Update will include new MRI analyses from the Phase 2b RewinD-LB clinical trial, status of global regulatory discussions, and finalized Phase 3 trial design Additional data from MRI analyses will...

Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit...

Cerrado Gold Announces Q4 and Annual 2025 Financial Results

New data for NMRA-511 supports unsurpassed clinical effect in a pre-specified population comparable to Rexulti and Auvelity pivotal studies  KOASTAL-2 and -3 fully enrolled in the first quarter of...

First Patient Dosed (FPD) in Phase 2a MAINSAIL Trial of NAV-240 in Hidradenitis Suppurativa (HS)Phase 1b Multiple Ascending Dose Study Demonstrates Favorable Profile for NAV-240 First Participant...

Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer...

PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in...

Laudio has been named to Fast Company’s World’s Most Innovative Companies of 2026 in spot number eight within the Human Resources category.

New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer’s disease (AD) co-pathology — experienced greater clinical benefit...